RT Journal Article
T1 Implications of maraviroc and/or rapamycin in a mouse model of fragility.
A1 Pérez-Martínez, Laura
A1 Romero, Lourdes
A1 Muñoz-Galván, Sandra
A1 Verdugo-Sivianes, Eva M
A1 Rubio-Mediavilla, Susana
A1 Oteo, José A
A1 Carnero, Amancio
A1 Blanco, José-Ramón
K1 CCR5 antagonist
K1 frailty
K1 myostatin
K1 rapamycin
AB As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10tm/tm [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated. Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p  MVC and RAPA show a protective role in some factors involved in frailty. More studies are needed to prove their clinical applications. Eighty male homozygous IL10KOs were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO receiving MVC in drinking water (MVC group), iii) IL10KO receiving RAPA in drinking water (RAPA group), and finally, iv) MVC-RAPA group that received MVC and RAPA in drinking water. Blood and muscle samples were analysed. Survival analysis, frailty index calculation, and functional assessment were also performed.
YR 2020
FD 2020-04-30
LK http://hdl.handle.net/10668/15471
UL http://hdl.handle.net/10668/15471
LA en
DS RISalud
RD Apr 9, 2025